Taken together, by using public WES data from 412 bladder cancer in the TCGA database we have identified 12 HLA-A*02:01 restricted MT peptides exhibiting stronger immunoreactivity in the periphery of BC patients among which six somatic mutations are partially associated with a better prognosis. This evidence concerns the gene HLA-A and urinary bladder carcinoma.